Clinical Trials Logo

Recurrent Angiosarcoma clinical trials

View clinical trials related to Recurrent Angiosarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05026736 Active, not recruiting - Clinical trials for Metastatic Angiosarcoma

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as sintilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sintilimab may help to control angiosarcoma.

NCT ID: NCT04668300 Recruiting - Clinical trials for Recurrent Osteosarcoma

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

DOSa
Start date: November 26, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.